FR 173657

Drug Profile

FR 173657

Alternative Names: FK 3657

Latest Information Update: 10 Sep 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fujisawa
  • Developer Fujisawa; Nonindustrial source
  • Class Analgesics; Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Angiogenesis inhibitors; Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Cancer; Ulcerative colitis

Most Recent Events

  • 08 Jun 2001 No-Development-Reported for Asthma in Japan (PO)
  • 06 Apr 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 02 Apr 2001 Preclinical development for Cancer in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top